ArticleRheumatology and therapy2022

Benefit-Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis.

Philip Conaghan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.